<DOC>
	<DOCNO>NCT01939223</DOCNO>
	<brief_summary>To evaluate compare efficacy safety regorafenib versus placebo subject colorectal cancer ( CRC ) curative resection liver metastasis completion plan chemotherapy .</brief_summary>
	<brief_title>COlorectal Cancer Treated With Adjuvant Regorafenib Versus Placebo After Curative Treatment Liver Metastases Randomized , Double-blind , Placebo‑Controlled Phase-III STudy</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<criteria>Have history primary adenocarcinoma colon / rectum Have history Stage IV Colorectal Cancer ( CRC ) metastases liver Have receive least 3 month , neoadjuvant , adjuvant , perioperative chemotherapy , include fluoropyrimidine either oxaliplatin irinotecan subject initial Stage IV CRC treat surgery curative intent primary metastatic lesion . The total chemotherapy administer , include administer prior liver resection , exceed 9 month . OR Have receive surgery curative intent primary CRC least 3 month , neoadjuvant , adjuvant , perioperative chemotherapy primary tumor , include fluoropyrimidine fluoropyrimidine either oxaliplatin irinotecan For subject liver metastasis develop &gt; 6 month complete treatment primary CRC undergone surgery curative intent liver metastasis , second course chemotherapy last least 3 month need administer , include fluoropyrimidine either oxaliplatin irinotecan . The second course chemotherapy exceed 9 month . For subject develop liver metastasis &gt; /=6 month complete treatment primary CRC undergone surgery curative intent liver metastasis , second course chemotherapy permit unless initial adjuvant therapy consist fluoropyrimidine monotherapy . Subjects received fluoropyrimidine alone must receive second course chemotherapy fluoropyrimidine either oxaliplatin irinotecan , exceed 9 months.For subject initial Stage I II disease , chemotherapy require primary CRC lesion treat surgery curative intent . These subject must receive chemotherapy treatment liver metastasis ( also treat surgery curative intent ) , must last least 3 month , include fluoropyrimidine either oxaliplatin irinotecan . The total course chemotherapy exceed 9 month . Prior randomization , histological confirmation CRC lesion adenocarcinoma ( subtypes adenocarcinoma , e.g . mucinous adenocarcinoma allow ) . Subjects CRC lesion histological type , include mixed type predominant adenocarcinoma , eligible randomize study treatment . Have pathologyproven complete removal primary liver metastatic CRC lesion . Subjects positive margin eligible study . Have adequate bone marrow function , liver function , renal function , measure follow laboratory assessment conduct within 7 day prior initiation study treatment : Total bilirubin &lt; /=1.5 time upper limit normal ( ULN ) Alanine aminotransferase aspartate aminotransferase &lt; /= 3 time ULN Lipase &lt; /=1.5 time ULN Serum creatinine &lt; /=1.5 time ULN Carcinoembryonic antigen ( CEA ) &lt; /=3 time ULN Glomerular filtration rate &gt; /=30 mL/min/1.73 m2 accord Modified Diet Renal Disease abbreviate formula International normalized ratio prothrombin time activate partial thromboplastic time &lt; /=1.5 time ULN . Subjects therapeutically treat agent warfarin heparin allow participate underlying abnormality coagulation parameter exist per medical history . Platelet count &gt; /=100,000 /mm3 , hemoglobin &gt; /=9 g/dL , absolute neutrophil count &gt; /= 1500/mm3 without transfusion granulocyte colony stimulate factor hematopoietic growth factor Alkaline phosphatase ≤ 2.5 time ULN Have CT MRI scan ( chest , abdomen , pelvis suspect site applicable ) determine eligibility randomization within 4 week prior randomization ( hereafter refer `` eligibility scan '' ) Have Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 within 14 day prior initiation study treatment If female childbearing potential , male , agree use adequate contraception ( e.g. , abstinence , intrauterine device , oral contraceptive , double barrier method ) base judgment investigator designate associate date ICF sign 8 week last dose study drug . Are take strong cytochrome P ( CYP ) CYP3A4 inhibitor ( eg , clarithromycin , indinavir , itraconazole , ketoconazole , nefazodone , nelfinavir , posaconazole , ritonavir , saquinavir , telithromycin , voriconazole ) strong CYP3A4 inducer ( eg , carbamazepine , phenobarbital , phenytoin , rifampin , St. John 's Wort ) . Have use biologic response modifier , granulocytecolony stimulate factor , within 3 week prior sign ICF . Have prior treatment regorafenib ( vascular endothelial growth factor receptor ) VEGFRtargeting kinase inhibitor . Have anticancer treatment follow liver resection exceed duration 6 month . Have treat biologics ( eg , antibody target VEGFR EGFR ) liver resection unless administration biologic start prior liver resection continue liver resection complete prespecified number cycle . Completed last dose chemotherapy last cancer surgery 10 week , whichever come later , prior randomization . Have extrahepatic metastatic disease . Suspicious lesion rigorously evaluate image technique and/or biopsy exclude extrahepatic metastatic disease prior submit central radiology review . Have systemic anticancer therapy include cytotoxic therapy , signal transduction inhibitor , immunotherapy , and/or hormonal therapy within 4 week prior initiation study treatment . Are pregnant breast feeding . Have prior concurrent cancer distinct primary site histology CRC within 5 year prior randomization EXCEPT curatively treat cervical cancer situ , nonmelanoma skin cancer , Stage 0 intramucosal gastric cancer endoscopic complete removal , superficial bladder tumor classify noninvasive tumor ( Ta ) , carcinoma situ ( Tis ) , tumor invades lamina propria ( T1 ) . Have congestive heart failure classify New York Heart Association Class 2 higher.Have unstable angina ( angina symptom rest ) newonset angina ≤ 3 month prior screen . Have myocardial infarction &lt; 6 month prior initiation study treatment . Have cardiac arrhythmia require antiarrhythmic therapy , exception beta blocker digoxin . Have uncontrolled hypertension ( systolic blood pressure [ SBP ] great than140 mmHg diastolic blood pressure [ DBP ] great 90 mmHg ) despite optimal medical management . Have pheochromocytoma . Have arterial venous thrombotic embolic event cerebrovascular accident ( include transient ischemic attack ) , deep vein thrombosis , pulmonary embolism within 6 month prior initiation study treatment . Have know history human immunodeficiency virus infection . Have either active chronic hepatitis B C require treatment antiviral therapy . Have seizure disorder require medication . Have evidence history bleed diathesis ( include mild hemophilia ) , irrespective severity . Have hemorrhage bleeding event &gt; /=Grade 3 ( NCICTCAE v 4.0 ) within 4 week prior initiation study treatment . Have serious unstable illness , medical , social , psychological condition , could jeopardize safety subject and/or his/her compliance study procedure , may interfere subject 's participation study evaluation study result .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Stage IV colorectal cancer / Liver Metastasis</keyword>
</DOC>